Locally Advanced and Metastatic Bladder Cancer: A Discussion on the Utility of Immunotherapy and Clinical Updates

Locally Advanced and Metastatic Bladder Cancer: A Discussion on the Utility of Immunotherapy and Clinical Updates

Faculty Presenters

Laura Bobolts, PharmD, BCOP
Senior Vice President, Clinical Strategy and Growth
Oncology Analytics, Inc.
Nova Southeastern University, College of Pharmacy
Fort Lauderdale, Florida

Kirollos Hanna, PharmD, BCPS, BCOP
Oncology Pharmacy Manager
M Health Fairview
Maple Grove, Minnesota

Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota

Sherry L. Mori Vogt, PharmD, BCOP
Lead Clinical Specialist Pharmacist, Oncology
The James Cancer Hospital at The Ohio State University
Columbus, Ohio
 
Program Description
Urothelial cancer (UC) is the most common type of bladder cancer and can involve the bladder, ureter, and renal pelvis. Platinum-based chemotherapy is the mainstay of treatment for locally advanced or metastatic UC (mUC). In patients who are unable to tolerate platinum agents or whose tumors express PD-L1, checkpoint inhibitors have a significant role. After first-line therapy, multiple advancements including use of maintenance therapy, indications for antibody-drug conjugates and targeted approaches, and growth of evidence for use of immune checkpoint inhibitors in the second-line setting have changed the treatment landscape. Multiple investigational approaches incorporating novel agents and combination therapy approaches are rapidly evolving. A further consideration is the economic burden of treatment with chemotherapy, checkpoint inhibitors, and emerging agents and treatment-related adverse effects. This panel will focus on the growth of therapies for this disease, challenges, and solutions to optimize overall patient outcomes.


Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: April 30, 2021
Expiration date: April 30, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Analyze the current standard treatment options for locally advanced or metastatic urothelial cancer (mUC) and evidence-based recommendations for their use
• Differentiate the efficacy, safety, and place in therapy of emerging treatment options and investigational combination therapies in locally advanced/mUC
• Explore the economic burden of bladder cancer and impact on health-related quality of life
• Examine the cost-effectiveness of standard, new, and emerging therapies for bladder cancer and their impact in patient management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-170-H01-P. The activity is available for CE credit through April 30, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Kirollos Hanna, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Seagen, AbbVie
• Speakers Bureau: Seagen, AbbVie, Astellas, Rigel Pharmaceuticals, Bristol Myers Squibb, BeiGene
• Stock/Stockholder: CVS

Sherry L. Mori Vogt, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:

• Advisory Board: Exelixis

Laura Bobolts, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms